ストックスクリーナーアプリを入手
280.68
1.95%
5.36
前日終値:
$275.32
開ける：
$276.41
24時間の取引高:
711.18K
Relative Volume:
1.35
時価総額：
$10.87B
収益：
$1.24B
当期純損益:
$42.23M
株価収益率:
264.79
EPS:
1.06
ネットキャッシュフロー:
$150.33M
1週間 パフォーマンス:
-5.60%
1か月 パフォーマンス:
+1.04%
6か月 パフォーマンス:
+18.01%
1年 パフォーマンス:
+39.27%
1日の値動き範囲:
$272.99
$281.63
1週間の範囲:
$265.00
$302.49
52週間の値動き範囲:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
PEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
280.68 | 11.51B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-14 | 開始されました | BofA Securities | Buy |
| 2025-01-21 | 開始されました | UBS | Buy |
| 2024-12-17 | 開始されました | Oppenheimer | Outperform |
| 2024-12-11 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | 開始されました | Stifel | Buy |
| 2024-09-03 | 開始されました | Leerink Partners | Outperform |
| 2024-07-31 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-07-31 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-07-19 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-29 | ダウングレード | Needham | Buy → Hold |
| 2023-01-30 | 開始されました | Piper Sandler | Overweight |
| 2022-11-04 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-10-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-09-09 | アップグレード | Needham | Hold → Buy |
| 2022-07-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-04-19 | 開始されました | Deutsche Bank | Buy |
| 2022-03-08 | 開始されました | Needham | Hold |
| 2021-09-16 | 開始されました | Truist | Buy |
| 2021-06-04 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-12-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-10-07 | 再開されました | Canaccord Genuity | Buy |
| 2020-09-29 | 開始されました | BTIG Research | Buy |
| 2020-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
| 2019-05-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-05-21 | 開始されました | William Blair | Outperform |
| 2018-10-29 | 再開されました | BofA/Merrill | Buy |
| 2018-10-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-02-21 | 開始されました | William Blair | Outperform |
| 2018-01-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2015-11-30 | 繰り返されました | Canaccord Genuity | Buy |
| 2015-10-13 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Penumbra Inc (PEN) 最新ニュース
Insider Sell Alert: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus
Here's Why Penumbra (PEN) is a Strong Momentum Stock - Yahoo Finance
Penumbra EVP Johanna Roberts sells $268,697 in stock - Investing.com
Here's Why Penumbra (PEN) is a Strong Growth Stock - Yahoo Finance
Stroke Awareness Month: Quick Action Can Save Lives - ABC Action News
Transcript : Penumbra, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
PEN Q1 Earnings Call: U.S. Thrombectomy Drives Outperformance as International Headwinds Persist - Yahoo Finance
PEN INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Continues Penumbra (PEN) Fraud Investigation In Light Of Company’s Admissions, Encourages Investors to Contact its Attorneys Now - ACCESS Newswire
Penumbra stock surges on approval hopes By Investing.com - Investing.com Canada
Should You Consider Adding Penumbra (PEN) To Your Portfolio? - Insider Monkey
Penumbra CFO Maggie Yuen sells $598,020 in common stock - Investing.com
3 Mid-Cap Medical Stocks Outperforming the Market - The Globe and Mail
Penumbra’s SWOT analysis: stock poised for growth amid innovation and challenges - Investing.com Australia
LAWSUIT FILED: Penumbra, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP - ACCESS Newswire
SHAREHOLDER ALERT: Penumbra, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm - ACCESS Newswire
Penumbra Inc.: Can Its Innovation & Product Pipeline Foster Long-Term Growth & Competitiveness? - Smartkarma
Penumbra, Inc. Reports First Quarter 2025 Financial Results - Eastern Progress
We Think You Can Look Beyond Penumbra's (NYSE:PEN) Lackluster Earnings - simplywall.st
Penumbra, Inc. to Present at the BofA Securities 2025 Health Car - GuruFocus
Exclusive: Penumbra Management Team Set for Key Presentation at BofA Healthcare Conference - Stock Titan
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference - Longview News-Journal
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
3 Reasons Growth Investors Will Love Penumbra (PEN) - Yahoo Finance
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Ischemic Neurological Interventional Medical Devices Market - openPR.com
Penumbra projects 12%-14% revenue growth for 2025 amid strong thrombectomy performance - MSN
Penumbra, Inc. (NYSE:PEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings Beat: Penumbra, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Penumbra, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Penumbra EVP Roberts sells shares worth $180,006 By Investing.com - Investing.com Canada
Penumbra Inc. Earnings Call Highlights Strong U.S. Growth - TipRanks
Penumbra EVP Roberts sells shares worth $180,006 - Investing.com
Abstract 160: Utilization of Penumbra MIDWAY 43 Catheter in Complex Neurovascular Interventions: Case Study Analysis - American Heart Association Journals
Stifel raises Penumbra stock price target to $318 - Investing.com Australia
Penumbra Reaches Analyst Target Price - Nasdaq
Penumbra First Quarter 2025 Earnings: Beats Expectations - Yahoo
Gabriel Grego, Police Investigator Among Short Sellers [In-Depth Profile] - ValueWalk
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst - Benzinga
Penumbra Inc (PEN) Trading 6.02% Higher on Apr 24 - GuruFocus
UBS raises Penumbra stock price target to $330, maintains Buy rating - Investing.com
Stifel raises Penumbra stock price target to $318 By Investing.com - Investing.com South Africa
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand - Yahoo Finance
UBS Adjusts Price Target on Penumbra to $330 From $320, Maintains Buy Rating - marketscreener.com
Truist Boosts Penumbra (PEN) Price Target Following Strong Q1 Pe - GuruFocus
Truist Boosts Penumbra (PEN) Price Target Following Strong Q1 Performance | PEN Stock News - GuruFocus
Penumbra Inc (PEN) 財務データ
収益
当期純利益
現金流量
EPS
0.85%
0.22%
大文字化:
|
ボリューム (24 時間):